
Zoladex LA 10.8 mg Injection
Salt Composition: Goserelin
Expiry Date: 01/2028
Inclusive of all taxes
1 Injection

Zoladex LA 10.8 mg Injection
1 Injection
Goserelin
Salt Composition
Goserelin
Storage
Below 25°C
Expiry Date
01/2028
Marketer
astrazeneca
Brand
zoladex
5966.png&w=1920&q=75)
MAGIC DEALS
Enquire
Apply Promo Code
Available CouponsZoladex LA 10.8 mg Injection
Inclusive of all taxes
In Stock
Authorized
Global Reach
Verified Logistics
The price displayed is inclusive of applicable taxes. Any additional fee (such as shipping fee, handling and/or platform fee etc.) will be clearly disclosed before you complete your purchase.
About The Product
Prostate Cancer
Zoladex 10.8mg Injection is an anticancer medicine with active ingredient Goserelin. It is prescribed to treat Prostate cancer in men. This medicine also given for Breast Cancer, Endometriosis, and Uterine Fibroids in women.
This medicine is a synthetic hormone that belongs to luteinizing hormone-releasing hormone (LHRH) agonists. It is used both in men and women but for different purposes. This injection should be administered under the skin by a doctor or experienced nurse. Don't self- administer it.
Overview
Zoladex LA 10.8 mg Injection contains goserelin acetate as its active ingredient and is classified under the category of drugs called GnRH agonists. This medication is used to treat hormone-related conditions like prostate cancer, breast cancer in women who have not yet undergone menopause, and endometriosis.
Zoladex LA 10.8 mg Injection mode of action is to lower the amounts of sex hormones that the body produces, such as testosterone in men and estrogen. The drug is available in the form of an implant that needs to be injected under the skin by a healthcare worker and is given every 12 weeks.
Common adverse effects of this Zoladex LA 10.8 mg Injection include hot flashes, sweating, headaches, mood swings, decreased libido, and reactions at the injection site. It should be taken only under medical supervision and in accordance with the instructions of the physician.
Quick Product Facts
Item | Detail |
Active ingredient | Goserelin 10.8 mg (as acetate) |
Form | Biodegradable implant in a single-dose SafeSystem syringe |
Marketer | AstraZeneca Pharma India Ltd |
Drug class | GnRH (LHRH) agonist |
Route and frequency | Subcutaneous, anterior abdominal wall, every 12 weeks |
Storage | Not above 30 °C ; protect from moisture |
Prescription status | Sold on the prescription of an oncologist only. |
Price control | Appears in NPPA's revised-MRP lists for anti-cancer drugs |
Price | Price of Zoladex LA 10.8 mg may vary depending on the location, pharmacy and availability |
Clinical Evidence for Zoladex LA 10.8 mg Injection
Zoladex 10.8 mg injection lowers testosterone as well as the 3.6 mg implant, and combined with radiotherapy it reduced local failure.
Study | Setting | Key result |
Stage B2-C trial | 466 men: Zoladex 3.6 mg + flutamide + radiotherapy vs radiotherapy alone | Local failure at 4 years 16% vs 33%. Distant spread 27% vs 36% (P = 0.058). Median disease-free survival 4.4 vs 2.6 years. |
Two controlled trials | 160 men with advanced prostate cancer: one 10.8 mg implant vs 3.6 mg implants every 4 weeks | Similar testosterone suppression. PSA fell 94% vs 92.5% at 3 months. |
Four 10.8 mg implants | Testosterone over 336 days | Kept in the castrate range over the dosing interval in about 91% of men (145 of 160). One man never kept it there. |
3.6 mg vs orchiectomy | Advanced prostate cancer | Long-term hormone and objective responses were similar. Survival was similar in a major trial. |
Zoladex LA 10.8 mg Injection Side Effects
Most men notice the effects of low testosterone. The most common are hot flushes, sexual dysfunction, fewer erections and urinary symptoms. Zoladex 10.8 mg injection reduces sex drive, hot flushes, erectile dysfunction, and frequent sweating.
Effect | 10.8 mg alone, weeks 12 to 48 (157 men) |
Hot flushes | 64% |
Diarrhoea | not listed |
Nausea | not listed |
Skin rash | not listed |
General pain | 14% |
Breast enlargement (gynaecomastia) | 8% |
Pelvic pain | 6% |
Bone pain | 6% |
Weakness (asthenia) | 5% |
Serious side effects
Tumor flare: testosterone rises briefly at the start. Bone pain can increase. Isolated cases of urinary blockage (ureteral obstruction) and spinal cord compression have occurred.
Allergy: antibody formation and acute anaphylactic reactions have been reported with GnRH agonists.
Blood sugar: high blood sugar and a higher risk of diabetes have been reported in men.
Heart and stroke: a small increase in heart attack, sudden cardiac death and stroke has been reported with GnRH agonists.
Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, and AGEP.
Heart rhythm: androgen deprivation may prolong the QT interval.
Injection-site injury: pain, bruising, bleeding, and, rarely, hemorrhagic shock needing transfusion or surgery. Extra care is needed in thin patients and those on full-dose anticoagulants.
Bones: lower bone density, osteoporosis, and fractures. Raised calcium can occur when cancer has spread to bone.
Pituitary: pituitary apoplexy, mostly within 2 weeks of the first dose, and pituitary tumors.
Mood and nerves: psychotic disorders, convulsions, and mood swings were reported after approval.
Critical Safety Warning
Call your local emergency number now for:
|
Zoladex LA 10.8 mg Injection Missed Dose
- If you miss your scheduled Zoladex LA 10.8 mg injection, contact your healthcare provider as soon as possible to arrange a new appointment.
- Every effort should be made to maintain the recommended 12-week dosing schedule.
- Do not delay your next injection or change your treatment schedule without consulting your doctor.
Safety Advice for Zoladex LA 10.8 mg Injection
Monitoring During Zoladex LA Treatment
Check | Label guidance [1] | Why |
Testosterone | Consider periodically if the expected response has not been reached; closely in obese men who have not responded | Confirm castrate levels |
PSA | As your oncologist decides | PSA fell 94% at 3 months in the trial |
Blood sugar and HbA1c | Periodically | Hyperglycaemia and diabetes |
Heart symptoms | Watch for signs of heart disease | Heart attack, stroke |
ECG and electrolytes | Consider periodically if QT risk | QT prolongation |
Bones | Watch bone health; bisphosphonate may help | Bone loss, fractures |
First month | Pain, urinary symptoms, nerve symptoms | Tumour flare |
Skin | Monitor for severe skin reactions | Interrupt if suspected; stop if confirmed |
Zoladex LA 10.8 mg Injection Fact Box
Item | Detail |
Brand Name | Zoladex LA 10.8 mg Injection |
Active ingredient | Goserelin 10.8 mg (as acetate) |
Form | Biodegradable implant in a single-dose SafeSystem syringe |
Marketer | AstraZeneca Pharma India Ltd |
Drug class | GnRH (LHRH) agonist |
Route and frequency | Subcutaneous, anterior abdominal wall, every 12 weeks |
Storage | Not above 30°C ; protect from moisture |
Chemical | Synthetic GnRH decapeptide analogue; goserelin molecular weight 1,269 Da |
Implant | 1.5 mm cylinder, total weight 36 mg, in a lactic and glycolic acid copolymer |
Peak and trough levels (10.8 mg) | Peak about 8.85 ng/mL at about 1.8 hours; trough about 0.37 ng/mL |
Protein binding | 27% |
Clearance | Mostly by hydrolysis; over 90% of a solution dose is excreted in urine |
Pregnancy | May cause fetal harm and pregnancy loss |
Zoladex LA 10.8 mg Injection Drug Interactions
Tell your team about every medicine you take, before starting Zoladex LA 10.8 mg Injection treatment.
Category | Interaction or Monitoring Details | Status |
General drug interactions | No formal drug-interaction studies have been conducted, and no confirmed interactions have been reported. Inform your doctor about all medicines you take. | Precaution required |
QT-prolonging medicines | Androgen deprivation may prolong the QT interval. Caution is advised with class IA and III antiarrhythmics, methadone, moxifloxacin, and antipsychotics. | Caution required |
Blood thinners | No specific drug interaction is listed, but anticoagulants may increase the risk of injection-site bleeding. | Bleeding risk |
Flutamide | Used in combination with Zoladex LA 10.8 mg Injection in certain prostate cancer treatment regimens involving radiotherapy (Stage B2–C). | Combined use |
Laboratory tests | Hormone test results, including pituitary and sex-hormone tests, may be misleading during treatment. | Monitoring required |
FAQs About Zoladex LA 10.8 mg Injection
Once every 12 weeks, which is 84 days. A doctor or nurse places one implant under the skin of the abdomen each time. The 3.6 mg implant is the one given every 28 days, so do not mix the two up. Keep to the schedule, although a delay of a few days is permissible.
References
TerSera Therapeutics. ZOLADEX (goserelin implant) 10.8 mg, US prescribing information, revised 09/2025.
NPPA. Revised MRP of non-scheduled anti-cancer drugs, lists of 28 October and 5 November 2026.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)